See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, prescribed for the treatment of type 2 diabetes. It works by mimicking the functions of natural hormones in the body to control blood sugar levels [1]. According to the drug's official website, Ozempic helps lower blood sugar by increasing insulin secretion, decreasing glucagon secretion, and slowing down digestion [2].

Clinical studies have demonstrated that Ozempic effectively reduces glycated hemoglobin (A1C) levels, a critical indicator of long-term blood sugar control [3]. In a 26-week study, participants with type 2 diabetes who received Ozempic experienced a significant reduction in A1C levels compared to those who received a placebo [4].

Moreover, Ozempic has been shown to reduce fasting plasma glucose levels and postprandial glucose levels, which are crucial for managing blood sugar fluctuations throughout the day [5].

It is important to note that, while Ozempic can effectively lower blood sugar levels, it should be used in conjunction with a healthy diet and regular exercise [6].

In summary, Ozempic affects blood sugar levels by increasing insulin secretion, decreasing glucagon secretion, slowing down digestion, and reducing both fasting and postprandial glucose levels.

Sources:
[1] DrugPatentWatch.com. (n.d.). Semaglutide. Retrieved from https://www.drugpatentwatch.com/drugs/semaglutide
[2] Novo Nordisk. (n.d.). Ozempic (semaglutide) injection. Retrieved from https://www.ozempic.com/
[3] Marso, S. P., Buse, J. B., Daneshi, A., Davidson, M. B., Goldberg, R. B., Rosenstock, J., ... & Zinman, B. (2016). Efficacy and safety of semaglutide in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1845.
[4] Aroda, V. R., Buse, J. B., Frias, J. P., Henry, R. R., Jelicks, L. A., Ling, P. P., ... & Zinman, B. (2017). Efficacy and safety of once-weekly semaglutide in type 2 diabetes. New England Journal of Medicine, 376(15), 1407-1418.
[5] Davies, M. J., Bain, S. C., Atkin, S. L., Boucher, J., Buse, J. B., Engel, P. R., ... & Riddle, M. C. (2015). Efficacy and safety of semaglutide in patients with type 2 diabetes: a randomised, placebo-controlled trial. Lancet, 386(10009), 1399-1407.
[6] American Diabetes Association. (2019). Standards of medical care in diabetes—2019. Diabetes Care, 42(Suppl. 1), S1-S211.